경직 치료 시장 규모, 점유율, 동향 분석 보고서 : 약물 계열별, 적응증별, 투여 경로별, 유통 채널별, 지역별 및 부문별 예측(2026-2033년)

Spasticity Treatment Market Summary

The global spasticity treatment market size was valued at USD 1.6 billion in 2025 and is projected to grow from USD 1.7 billion in 2026 to USD 2.6 billion by 2033, at a CAGR of 6.2% from 2026 to 2033. North America dominated the market, accounting for the largest global share of 41.2% 2025. The market growth is driven by the increasing diagnosis of neurological disorders that commonly lead to muscle spasticity, including multiple sclerosis, cerebral palsy, stroke, traumatic brain injury, and spinal cord injury.

The growing aging population has contributed to a higher number of stroke survivors and patients with chronic neurological conditions requiring long-term spasticity management. Treatment continues to rely on a combination of oral medications, botulinum toxin injections, intrathecal baclofen therapy, physical rehabilitation, and surgical interventions based on disease severity and patient needs. Healthcare providers are placing greater emphasis on multidisciplinary care to improve mobility, reduce pain, prevent contractures, and enhance functional independence. The availability of advanced rehabilitation services, improved access to specialist neurology care, and increasing awareness of early intervention support treatment adoption across developed healthcare systems. At the same time, ongoing clinical research focused on novel neurotoxin formulations, improved drug delivery methods, and regenerative approaches is expanding future treatment possibilities while addressing the limitations associated with long-term symptom management.

Global Spasticity Treatment Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global spasticity treatment market report based on drug class, indication, route of administration, distribution channel, and region:

• Drug Class Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Skeletal Muscle Relaxants
• Botulinum Neurotoxin Therapies
• Benzodiazepines
• Others
• Indication Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Multiple Sclerosis
• Cerebral Palsy
• Stroke
• Spinal Cord Injury
• Traumatic Brain Injury
• Others
• Route of Administration Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Oral
• Injectable
• Intrathecal
• Distribution Channel Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Class
  • 1.2.2. Indication
  • 1.2.3. Route of Administration
  • 1.2.4. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Spasticity Treatment Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Spasticity Treatment Market: Drug Class Business Analysis

• 4.1. Drug Class Market Share, 2025 & 2033
• 4.2. Drug Class Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Million/Billion)
• 4.4. Skeletal Muscle Relaxants
  • 4.4.1. Skeletal Muscle Relaxants Market, 2021 - 2033 (USD Million/Billion)
• 4.5. Botulinum Neurotoxin Therapies
  • 4.5.1. Botulinum Neurotoxin Therapies Market, 2021 - 2033 (USD Million/Billion)
• 4.6. Benzodiazepines
  • 4.6.1. Benzodiazepines Market, 2021 - 2033 (USD Million/Billion)
• 4.7. Others
  • 4.7.1. Others Market, 2021 - 2033 (USD Million/Billion)

Chapter 5. Spasticity Treatment Market: Indication Business Analysis

• 5.1. Indication Market Share, 2025 & 2033
• 5.2. Indication Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million/Billion)
• 5.4. Multiple Sclerosis
  • 5.4.1. Multiple Sclerosis Market, 2021 - 2033 (USD Million/Billion)
• 5.5. Cerebral Palsy
  • 5.5.1. Cerebral Palsy Market, 2021 - 2033 (USD Million/Billion)
• 5.6. Stroke
  • 5.6.1. Stroke Market, 2021 - 2033 (USD Million/Billion)
• 5.7. Spinal Cord Injury
  • 5.7.1. Spinal Cord Injury Market, 2021 - 2033 (USD Million/Billion)
• 5.8. Traumatic Brain Injury
  • 5.8.1. Traumatic Brain Injury Market, 2021 - 2033 (USD Million/Billion)
• 5.9. Others
  • 5.9.1. Others Market, 2021 - 2033 (USD Million/Billion)

Chapter 6. Spasticity Treatment Market: Route of Administration Business Analysis

• 6.1. Route of Administration Market Share, 2025 & 2033
• 6.2. Route of Administration Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million/Billion)
• 6.4. Oral
  • 6.4.1. Oral Market, 2021 - 2033 (USD Million/Billion)
• 6.5. Injectable
  • 6.5.1. Injectable Market, 2021 - 2033 (USD Million/Billion)
• 6.6. Intrathecal
  • 6.6.1. Intrathecal Market, 2021 - 2033 (USD Million/Billion)

Chapter 7. Spasticity Treatment Market: Distribution Channel Business Analysis

• 7.1. Distribution Channel Market Share, 2025 & 2033
• 7.2. Distribution Channel Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million/Billion)
• 7.4. Hospital Pharmacies
  • 7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million/Billion)
• 7.5. Retail Pharmacies
  • 7.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million/Billion)
• 7.6. Online Pharmacies
  • 7.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million/Billion)

Chapter 8. Spasticity Treatment Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2025 & 2033
• 8.2. Regional Market Dashboard
• 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 8.4. North America
  • 8.4.1. North America Spasticity Treatment Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million/Billion)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Target Disease Prevalence
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Reimbursement Framework
    • 8.4.2.5. U.S. Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Target Disease Prevalence
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Reimbursement Framework
    • 8.4.3.5. Canada Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Target Disease Prevalence
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Reimbursement Framework
    • 8.4.4.5. Mexico Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 8.5. Europe
  • 8.5.1. Europe Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Target Disease Prevalence
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement Framework
    • 8.5.2.5. UK Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Target Disease Prevalence
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement Framework
    • 8.5.3.5. Germany Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Target Disease Prevalence
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Reimbursement Framework
    • 8.5.4.5. France Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Target Disease Prevalence
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Reimbursement Framework
    • 8.5.5.5. Italy Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Target Disease Prevalence
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Reimbursement Framework
    • 8.5.6.5. Spain Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.5.7. Denmark
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Target Disease Prevalence
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Reimbursement Framework
    • 8.5.7.5. Denmark Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.5.8. Sweden
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Target Disease Prevalence
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Reimbursement Framework
    • 8.5.8.5. Sweden Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Target Disease Prevalence
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Reimbursement Framework
    • 8.5.9.5. Norway Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Target Disease Prevalence
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement Framework
    • 8.6.2.5. Japan Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Target Disease Prevalence
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement Framework
    • 8.6.3.5. China Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Target Disease Prevalence
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement Framework
    • 8.6.4.5. India Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.6.5. Australia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Target Disease Prevalence
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement Framework
    • 8.6.5.5. Australia Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.6.6. South Korea
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Target Disease Prevalence
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. Reimbursement Framework
    • 8.6.6.5. South Korea Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Target Disease Prevalence
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Reimbursement Framework
    • 8.6.7.5. Thailand Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 8.7. Latin America
  • 8.7.1. Latin America Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Target Disease Prevalence
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Reimbursement Framework
    • 8.7.2.5. Brazil Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Target Disease Prevalence
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Reimbursement Framework
    • 8.7.3.5. Argentina Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 8.8. Middle East and Africa
  • 8.8.1. Middle East and Africa Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Target Disease Prevalence
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. Reimbursement Framework
    • 8.8.2.5. South Africa Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Target Disease Prevalence
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Reimbursement Framework
    • 8.8.3.5. Saudi Arabia Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Target Disease Prevalence
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. Reimbursement Framework
    • 8.8.4.5. UAE Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Target Disease Prevalence
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Reimbursement Framework
    • 8.8.5.5. Kuwait Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 9. Competitive Landscape

• 9.1. Participant Overview
• 9.2. Company Market Position Analysis
• 9.3. Company Categorization
• 9.4. Strategy Mapping
• 9.5. Company Profiles/Listing
  • 9.5.1. AbbVie Inc.
    • 9.5.1.1. Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. Ipsen S.A.
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. Merz Therapeutics GmbH
    • 9.5.3.1. Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. Eisai Co., Ltd.
    • 9.5.4.1. Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. Teva Pharmaceutical Industries Ltd.
    • 9.5.5.1. Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. Viatris Inc.
    • 9.5.6.1. Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. Amneal Pharmaceuticals, Inc.
    • 9.5.7.1. Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. Sun Pharmaceutical Industries Ltd.
    • 9.5.8.1. Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product Benchmarking
    • 9.5.8.4. Strategic Initiatives
  • 9.5.9. Hikma Pharmaceuticals PLC
    • 9.5.9.1. Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Product Benchmarking
    • 9.5.9.4. Strategic Initiatives
  • 9.5.10. Endo, Inc.
    • 9.5.10.1. Overview
    • 9.5.10.2. Financial Performance
    • 9.5.10.3. Product Benchmarking
    • 9.5.10.4. Strategic Initiatives